vs
Side-by-side financial comparison of Clearfield, Inc. (CLFD) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
Clearfield, Inc. is the larger business by last-quarter revenue ($34.3M vs $18.6M, roughly 1.8× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -1.8%, a 67.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs -3.2%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -3.5%).
Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
CLFD vs SCYX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $34.3M | $18.6M |
| Net Profit | $-614.0K | $12.3M |
| Gross Margin | 33.2% | — |
| Operating Margin | -5.3% | 56.3% |
| Net Margin | -1.8% | 65.7% |
| Revenue YoY | -3.2% | 1808.5% |
| Net Profit YoY | 67.8% | 376.5% |
| EPS (diluted) | $-0.04 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $34.3M | $18.6M | ||
| Q3 25 | $23.4M | $334.0K | ||
| Q2 25 | $49.9M | $1.4M | ||
| Q1 25 | $47.2M | $257.0K | ||
| Q4 24 | $29.7M | $977.0K | ||
| Q3 24 | $5.6M | $660.0K | ||
| Q2 24 | $48.8M | $736.0K | ||
| Q1 24 | $36.9M | $1.4M |
| Q4 25 | $-614.0K | $12.3M | ||
| Q3 25 | $-9.1M | $-8.6M | ||
| Q2 25 | $1.6M | $-6.9M | ||
| Q1 25 | $1.3M | $-5.4M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-2.8M | ||
| Q2 24 | $-447.0K | $-14.5M | ||
| Q1 24 | $-5.9M | $411.0K |
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | — | ||
| Q2 25 | 30.5% | — | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.9% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | -5.3% | 56.3% | ||
| Q3 25 | 10.3% | -2516.5% | ||
| Q2 25 | 3.0% | -701.0% | ||
| Q1 25 | 0.6% | -3350.2% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | -4.7% | -1255.0% | ||
| Q1 24 | -26.4% | -692.5% |
| Q4 25 | -1.8% | 65.7% | ||
| Q3 25 | -38.8% | -2572.2% | ||
| Q2 25 | 3.2% | -504.8% | ||
| Q1 25 | 2.8% | -2097.7% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -425.5% | ||
| Q2 24 | -0.9% | -1964.4% | ||
| Q1 24 | -16.0% | 29.9% |
| Q4 25 | $-0.04 | $0.25 | ||
| Q3 25 | $-0.65 | $-0.17 | ||
| Q2 25 | $0.11 | $-0.14 | ||
| Q1 25 | $0.09 | $-0.11 | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | $-0.04 | $-0.30 | ||
| Q1 24 | $-0.40 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $96.4M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $249.7M | $49.4M |
| Total Assets | $268.1M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $96.4M | $40.0M | ||
| Q3 25 | $106.0M | $37.9M | ||
| Q2 25 | $117.2M | $44.8M | ||
| Q1 25 | $112.0M | $40.6M | ||
| Q4 24 | $113.0M | $59.3M | ||
| Q3 24 | $129.0M | $68.8M | ||
| Q2 24 | $123.8M | $73.0M | ||
| Q1 24 | $142.9M | $80.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $249.7M | $49.4M | ||
| Q3 25 | $256.2M | $36.4M | ||
| Q2 25 | $264.5M | $44.5M | ||
| Q1 25 | $265.9M | $50.5M | ||
| Q4 24 | $267.4M | $55.1M | ||
| Q3 24 | $275.8M | $58.5M | ||
| Q2 24 | $274.6M | $60.4M | ||
| Q1 24 | $279.2M | $74.1M |
| Q4 25 | $268.1M | $59.0M | ||
| Q3 25 | $306.2M | $51.1M | ||
| Q2 25 | $314.7M | $60.7M | ||
| Q1 25 | $310.9M | $67.9M | ||
| Q4 24 | $303.2M | $90.6M | ||
| Q3 24 | $315.3M | $99.0M | ||
| Q2 24 | $318.1M | $107.8M | ||
| Q1 24 | $315.4M | $118.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | — | ||
| Q2 24 | 0.01× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.4M | $18.4M |
| Free Cash FlowOCF − Capex | $-2.4M | — |
| FCF MarginFCF / Revenue | -7.1% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.4M | $18.4M | ||
| Q3 25 | — | $-8.7M | ||
| Q2 25 | $7.9M | $-7.5M | ||
| Q1 25 | $3.0M | $-7.5M | ||
| Q4 24 | $7.2M | $-24.0M | ||
| Q3 24 | $22.2M | $765.0K | ||
| Q2 24 | $4.0M | $-10.9M | ||
| Q1 24 | $-5.7M | $-4.0M |
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $654.0K | — | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $18.2M | — | ||
| Q2 24 | $2.8M | — | ||
| Q1 24 | $-7.7M | — |
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 323.0% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | -20.8% | — |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 71.4% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLFD
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
